🔍
Showing 503 articles
← Return to All Dispatches / Health & Medicine
#448 Health & Medicine • Updated Nov 15, 2026

The Fastest-Growing Filovirus Outbreak: Inside the 2026 Ebola Crisis

Biology • Public Health • Urban Environment

Introduction: The 2026 Bundibugyo Ebolavirus Emergency and Regional Spillover Context

On May 17, 2026, the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) following a high-mortality viral hemorrhagic fever epidemic across the Democratic Republic of the Congo (DRC) and Uganda[1][3][4]. The etiologic agent, Bundibugyo virus (BDBV; Orthoebolavirus bundibugyoense), is a filovirus lacking licensed vaccines or approved targeted therapeutics[1][12][13]. Marking the DRC's 17th Ebola outbreak since 1976, the epidemic unfolded amid eastern DRC conflict and displacement, reaching ~1,780 confirmed cases and ~602 deaths by early July 2026—the third-largest Ebola outbreak and fastest-growing filovirus epidemic in history[2][6][7]. Previously recorded only in 2007 in western Uganda (~34% CFR) and 2012 in Isiro, DRC, BDBV re-emerged alongside the late-2025 Kasai Zaire ebolavirus outbreak (64 cases, 45 deaths) and Marburg outbreaks in Uganda and Ethiopia[10][12][14][16]. Although surveillance funding cuts delayed detection[8], the crisis mobilized in-field genomic evolution tracking, epidemiological modeling, and the adaptive PARTNERS trial[10][11].

Spatiotemporal Epidemiology, R0 Dynamics, and Surveillance

The earliest retrospective hemorrhagic case presented on April 24, 2026, in the mining town of Mongbwalu, Ituri Province, after weeks of cryptic spread masked by symptoms resembling endemic malaria and typhoid and low (~10%) overt hemorrhage[2][14][20]. Following a May 5 alert, Kinshasa's INRB confirmed BDBV on May 14 via pan-filovirus RT-PCR after Zaire-specific GeneXpert assays returned false negatives[2][10][22].

Geographic LocationConfirmed CasesConfirmed DeathsCase Fatality Rate (CFR)Epidemiological Context
Ituri Province, DRC1,60151131.9%Primary epicenter across 25 of 36 health zones[2].
North Kivu, DRC1558856.8%Secondary epicenter amid conflict and displacement[2].
South Kivu, DRC3133.3%Limited localized transmission[2].
Tshopo Province, DRC2 (Suspected)PendingN/AKisangani cases linked to Nia-Nia health zone[24].
Kampala/Wakiso, Uganda20210.0%Cross-border cluster with nosocomial transmission[6].
France100.0%Medically evacuated physician from the DRC[3].
Global Cumulative~1,780~602~33.8%Third-largest Ebola outbreak globally[2].

Branching-process models estimated the basic reproduction number (R0) at 1.31–1.55 with an 11.7-day doubling time (95% HPD: 6.8–17.5 days)[19][29]. Spread was amplified by nosocomial infections (>100 healthcare workers, 25 deaths) and post-mortem funeral contact, as 93% (400/430) of early investigated deaths occurred in the community[4][26][30]. On July 2, 2026, the WHO granted Emergency Use Listing (EUL) to the first BDBV-specific molecular assay alongside border exit screening[4][31].

Molecular Virology, NPC1 Entry, and Comparative Pathogenesis

BDBV possesses an ~18.9 kb linear, negative-sense, single-stranded RNA genome (~42% guanine-cytosine content) encoding seven structural proteins and edited non-structural glycoproteins[33][35][36].

Viral ProteinGenetic DesignationStructural and Functional CharacteristicsReference Implications
Nucleoprotein (NP)NPForms the helical nucleocapsid core by binding genomic RNA and coordinates ribonucleoprotein (RNP) replication.[33][35][38]
Polymerase Cofactor (VP35)VP35Essential polymerase cofactor; binds dsRNA to inhibit RIG-I-like receptors and type I interferon (IRF3/IRF7) induction.[35][38][39]
Matrix Protein (VP40)VP40Coordinates plasma-membrane viral assembly, budding, and transcriptional regulation.[35][38][39]
Glycoprotein (GP)GPClass I fusion trimer cleaved into GP1 (attachment) and GP2 (fusion); primary neutralizing antibody target.[35][38][40]
Secreted Glycoproteins (sGP, ssGP)GP (edited)Soluble non-structural proteins secreted from infected cells as antibody-absorbing immunological decoys.[35][38][39]
Transcriptional Activator (VP30)VP30Minor nucleoprotein essential for viral mRNA transcription initiation.[35][38]
Membrane-Associated Protein (VP24)VP24Binds host karyopherin-α to block nuclear import of phosphorylated STAT1, paralyzing interferon signaling.[33][38]
Large Protein (L)LViral RNA-dependent RNA polymerase catalyzing mRNA transcription and full-length genome replication.[33][35][38]

Following TIM-1/lectin attachment and uptake via macropinocytosis or clathrin-mediated endocytosis, endolysosomal cathepsin proteases cleave the GP1 glycan cap and mucin-like domain (MLD), exposing the receptor-binding domain to engage the Niemann-Pick C1 (NPC1) cholesterol transporter and trigger GP2 internal fusion loop (IFL) insertion into the endosomal membrane, releasing the RNP into the cytoplasm[34][40]. Compared to Zaire ebolavirus in human peripheral blood mononuclear cells, BDBV replicates 1–2 logs lower and induces 2- to 10-fold lower proinflammatory cytokines (TNF-α, MCP-1, IL-1β, MIP-1α, IL-10) and slower macrophage death—explaining its ~34% CFR but prolonging infectious mobility[15][42][43].

Genomic Phylodynamics and the Molecular Clock

Oxford Nanopore MinION sequencing and ARTIC workflows mapped to the 2007 Butalya reference (NC_014373.1) showed the 2026 lineage forms a distinct monophyletic clade separated from 2007 and 2012 strains, confirming a de novo zoonotic spillover[10][19][32]. Bayesian molecular clock models estimated a rate of 1.10–1.12 × 10-3 substitutions/site/year, placing the tMRCA in mid-March 2026 (95% HPD: early February to mid-April)[29]. Across 23 early SNPs, non-synonymous amino acid substitutions clustered in the GP mucin-like domain (GP:P365S, GP:P367L, GP:P389L, GP:R394G) alongside L-gene mutation T18905G, under strong purifying selection[19][38][44].

Adaptive Clinical Trials: Remdesivir, MBP134AF, and Obeldesivir PEP

Because licensed Zaire countermeasures (Ervebo, Inmazeb, Ebanga) lack cross-protection against BDBV and rVSV/ChAdOx BDBV vaccine candidates remain months from Phase 1 trials[15][47], the WHO, INRB, ITM Antwerp, and Oxford launched the adaptive randomized PARTNERS trial on July 2, 2026, alongside the EBO-PEP prophylaxis platform[11][48][50]:

  1. Remdesivir: An adenosine triphosphate (ATP) prodrug analog that induces delayed chain termination in the conserved filovirus L RNA polymerase[14][47][51].
  2. MBP134AF: A pan-ebolavirus cocktail of two survivor-derived human IgG1 monoclonal antibodies (ADI-15878 and affinity-matured ADI-23774)[52][53][56]. Resolved by cryogenic electron microscopy, ADI-15878 locks the conserved GP2 internal fusion loop and HR1 protomer interface, while Fc afucosylation enhances FcγRIIIa binding on Natural Killer cells to drive antibody-dependent cellular cytotoxicity (ADCC), reversing lethal NHP BDBV challenge in a single dose[40][41][56][58].
  3. Obeldesivir (ODV) and Galidesivir: Evaluated in EBO-PEP, oral obeldesivir models project a >64% reduction in healthcare-worker mortality at 80% efficacy and coverage, complemented by compassionate-use MEURI clearance for galidesivir in Uganda[28][48][61].

Conclusion: Frontline Bottlenecks and Global Health Security

Despite rapid sequencing and trials, containment in Ituri and North Kivu was hindered by strikes among unpaid responders lacking PPE, armed conflict across two million displaced residents, arson attacks on treatment centers, and prior USAID surveillance cuts[2][8][52][63][64]. Halting the 2026 Bundibugyo crisis requires pairing pan-filovirus immunotherapeutics like MBP134AF with sustained frontline operational financing.

Updates… (Nov 15, 2026): Between late October and mid-November 2026, cumulative DRC Bundibugyo virus disease cases surpassed 11,100 confirmed infections and 5,400 deaths across eight provinces. Uganda’s secondary outbreak was officially declared ended on August 27, 2026 (21 cases, 3 deaths), while imported clusters in Kenya and Nigeria were contained without sustained community transmission; the Tumaini Phase 2/3 vaccine trial also expanded alongside PARTNERS to evaluate ChAdOx1-BDBV and mRNA-1469.

Works Cited

  1. Ebola outbreak - DRC 2026 - World Health Organization (WHO), https://www.who.int/emergencies/situations/ebola-outbreak---drc-2026
  2. 2026 Ebola epidemic - Wikipedia, https://en.wikipedia.org/wiki/2026_Ebola_epidemic
  3. Ongoing outbreak in the Democratic Republic of the Congo | WHO | Regional Office for Africa, https://www.afro.who.int/health-topics/ebola-disease/outbreak-drc-26
  4. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a public health emergency of international concern, https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern
  5. Researchers launch study on Ebola treatments as Congo outbreak worsens, https://apnews.com/article/ebola-bundibugyo-remdesivir-mbp134-congo-7dd42ecd5ff75a4f1e255db26677a778
  6. Ebola Outbreak: Current Situation - CDC, https://www.cdc.gov/ebola/situation-summary/index.html
  7. Ebola outbreak is 'fastest growing ever' as 600 die, https://www.courthousenews.com/ebola-outbreak-is-fastest-growing-ever-as-600-die/
  8. What will define Elon Musk’s legacy? Doge cuts to USAID Ebola programs, https://www.theguardian.com/technology/2026/jul/07/elon-musk-doge-cuts-usaid-ebola
  9. Africa Has Faced a Rare Ebola Outbreak for Months. Here’s What to Know., https://www.cfr.org/articles/africa-has-faced-a-rare-ebola-outbreak-for-months-heres-what-to-know
  10. Initial genomes from May 2026 Bundibugyo Virus Disease Outbreak in the Democratic Republic of the Congo and Uganda - Virological, https://virological.org/t/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/1032
  11. Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease - World Health Organization (WHO), https://www.who.int/news/item/02-07-2026-patient-enrolment-begins-in-a-scientific-trial-to-identify-the-first-effective-treatments-for-bundibugyo-virus-disease
  12. Bundibugyo ebolavirus - Wikipedia, https://en.wikipedia.org/wiki/Bundibugyo_ebolavirus
  13. Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus - Preprints.org, https://www.preprints.org/manuscript/202606.0743
  14. WHO announces 2 trials of experimental drugs in Ebola outbreak - CIDRAP, https://www.cidrap.umn.edu/ebola/who-announces-2-trials-experimental-drugs-ebola-outbreak
  15. What to know about the Bundibugyo virus, form of Ebola causing an outbreak in Congo, https://www.pbs.org/newshour/health/what-to-know-about-the-bundibugyo-virus-form-of-ebola-causing-an-outbreak-in-congo
  16. Ebola and Marburg haemorrhagic fevers: outbreaks and case locations - GOV.UK, https://www.gov.uk/guidance/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations
  17. History of Ebola Outbreaks - CDC, https://www.cdc.gov/ebola/outbreaks/index.html
  18. Ebola Disease Outbreak in the Democratic Republic of the Congo and Uganda | HAN - CDC, https://www.cdc.gov/han/php/notices/han00530.html
  19. Molecular evolutionary analysis of the current Bundibugyo virus disease outbreak in DRC and Uganda - Virological, https://virological.org/t/molecular-evolutionary-analysis-of-the-current-bundibugyo-virus-disease-outbreak-in-drc-and-uganda/1042
  20. 2026 Ebola virus outbreak: Facts, FAQs, and how to help | World Vision, https://www.worldvision.org/health-news-stories/2014-ebola-virus-outbreak-facts
  21. Bundibugyo, the rare virus causing a deadly new Ebola outbreak, has no vaccine yet. Here's what we know, https://www.gavi.org/vaccineswork/bundibugyo-rare-virus-causing-deadly-new-ebola-outbreak-drc-has-no-vaccine-yet
  22. DR Congo/Uganda: Ebola Outbreak - May 2026 | ReliefWeb, https://reliefweb.int/disaster/ep-2026-000071-cod
  23. Bundibugyo Virus – What it is and what it is not - CEPI, https://cepi.net/bundibugyo-virus-what-it-and-what-it-not
  24. Ebola disease outbreak in the Democratic Republic of the Congo and Uganda - ECDC, https://www.ecdc.europa.eu/en/ebola-outbreak-democratic-republic-congo-and-uganda
  25. Ebola death toll in Congo reaches 600, as new cases suspected in previously unaffected province, https://www.yourvalley.net/stories/ebola-death-toll-in-congo-reaches-600-as-new-cases-suspected-in-previously-unaffected-province,703663
  26. Ebola death toll hits 600 in DR Congo as virus reported in new province, https://www.aa.com.tr/en/africa/ebola-death-toll-hits-600-in-dr-congo-as-virus-reported-in-new-province/3992905
  27. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda, https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON612
  28. Evaluating the impact of antiviral post-exposure prophylaxis for health-care workers during ebolavirus outbreaks: a modelling study | medRxiv, https://www.medrxiv.org/content/10.64898/2026.06.26.26356717v1.full-text
  29. Genomic epidemiology of the ongoing 2026 Bundibugyo Virus Disease outbreak in the Democratic Republic of the Congo - Virological, https://virological.org/t/genomic-epidemiology-of-the-ongoing-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo/1045
  30. When Caregivers Become Patients: Frontline Vulnerability in the Bundibugyo Outbreak Response, https://www.infectioncontroltoday.com/view/when-caregivers-become-patients-frontline-vulnerability-bundibugyo-outbreak-response
  31. WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing, https://www.who.int/news/item/02-07-2026-who-adds-first-diagnostic-test-for-ebola-bundibugyo-virus-to-its-emergency-use-listing
  32. expert reaction to initial genomes of the Bundibugyo virus from the outbreak in the Democratic Republic of the Congo and Uganda | Science Media Centre, https://www.sciencemediacentre.org/expert-reaction-to-initial-genomes-of-the-bundibugyo-virus-from-the-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/
  33. Ebolavirus Classification Based on Natural Vectors - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC4484716/
  34. Orthoebolaviruses: Infectious substances pathogen safety data sheet - Canada.ca, https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/ebolavirus.html
  35. Genus: Orthoebolavirus | ICTV, https://ictv.global/report/chapter/filoviridae/filoviridae/orthoebolavirus
  36. Orthoebolavirus ~ ViralZone - Expasy, https://viralzone.expasy.org/207
  37. Bundibugyo virus genome assembly ViralProj51245 - NCBI - NLM - NIH, https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000889155.1/
  38. Genomic Epidemiology and Molecular Characteristics of Bundibugyo Virus - Public Health Ontario, https://www.publichealthontario.ca/-/media/Documents/B/26/bundibugyo-virus-genomic-epidemiology-molecular-characteristics.pdf?rev=93d3703a06c74be099f0e96e59b37abd&sc_lang=en
  39. Bundibugyo virus | Taxonomy - UniProt, https://www.uniprot.org/taxonomy/565995
  40. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development - Frontiers, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.808047/full
  41. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6174886/
  42. Comparison of Zaire and Bundibugyo Ebolavirus Polymerase Complexes and Susceptibility to Antivirals through a Newly Developed Bundibugyo Minigenome System - ASM Journals, https://journals.asm.org/doi/10.1128/jvi.00643-21
  43. Reduced virus replication, proinflammatory cytokine production, and delayed macrophage cell death in human PBMCs infected with the newly discovered Bundibugyo ebolavirus relative to Zaire ebolavirus - PubMed, https://pubmed.ncbi.nlm.nih.gov/20394957/
  44. A Constrained-Evolution Hypothesis for the 2026 Bundibugyo Ebolavirus Outbreak in the Democratic Republic of the Congo: Predictable Mutational Pathways, Diagnostic Fragility, and Short-Horizon Epidemic Trajectories - Preprints.org, https://www.preprints.org/manuscript/202605.1844
  45. 2020 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10849974/
  46. Complete Genome Sequence of a New Ebola Virus Strain Isolated during the 2017 Likati Outbreak in the Democratic Republic of the Congo - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6522791/
  47. Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus - Nature, https://media.nature.com/original/magazine-assets/d41573-026-00094-6/52506132
  48. EBOla Post-Exposure Prophylaxis (EBO-PEP) - ClinicalTrials.Veeva, https://ctv.veeva.com/study/ebola-post-exposure-prophylaxis
  49. EBO-PEP Clinical Trial for Ebola Zaïre outbreak, https://cdn.who.int/media/docs/default-source/consultation-rdb/6_ebopep.pdf?sfvrsn=6326ba1d_1
  50. PARTNERS – Platform adaptive randomized trial for new and repurposed Filovirus treatments – Core Trial Protocol - World Health Organization (WHO), https://www.who.int/publications/m/item/partners-platform-adaptive-randomized-trial-for-new-and-repurpose-filovirus-treatments-core-trial-protocol
  51. Ebola: New trial to test treatments for unchallenged viral strain - Medical News Today, https://www.medicalnewstoday.com/articles/ebola-treatment-clinical-trial-bundibugyo-virus-3-questions
  52. Clinical trial for Ebola therapies begins in DR Congo | CIDRAP, https://www.cidrap.umn.edu/ebola/clinical-trial-ebola-therapies-begins-dr-congo
  53. Frequently Asked Questions - Bundibugyo and MBP134 - Mapp Biopharmaceutical, Inc., https://mappbio.com/frequently-asked-questions-bundibugyo-and-mbp134/
  54. WHO Launches PARTNERS Trial to Evaluate MBP134 and Remdesivir for Bundibugyo Ebola in DR Congo - Pharmacally, https://pharmacally.com/who-launches-partners-trial-to-evaluate-mbp134-and-remdesivir-for-bundibugyo-ebola-in-dr-congo/
  55. ADI-15878 (ADI-15742) | Anti-Envelope glycoprotein, GP2 mAb | MedChemExpress, https://www.medchemexpress.com/adi-15878.html
  56. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection - The Chandran Lab, https://www.chandranlab.org/blog/2017/5/11/a-single-residue-in-ebola-virus-receptor-npc1-influences-cellular-host-range-in-reptiles-hzdr6-db8h6-apg5t-3hlpd-e8mhm-jyxe6-8nf22-dpypd-4jkxd-abx9m
  57. Rare Antibodies Show How to Neutralize the Many Types of Ebola, https://www.aps.anl.gov/APS-Science-Highlight/2018/rare-antibodies-show-how-to-neutralize-the-many-types-of-ebola
  58. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC6396299/
  59. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection - PubMed, https://pubmed.ncbi.nlm.nih.gov/30629917/
  60. Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9228268/
  61. Galidesivir cleared for use in Bundibugyo Ebola epidemic - CBRNe World, https://cbrneworld.com/news/galidesivir-cleared-for-use-in-bundibugyo-ebola-epidemic
  62. Government approvals secured for the use of Galidesivir as a treatment for Bundibugyo Ebola epidemic in Africa - Investing News Network, https://investingnews.com/government-approvals-secured-for-the-use-of-galidesivir-as-a-treatment-for-bundibugyo-ebola-epidemic-in-africa/
  63. DR Congo's Ebola outbreak claims 506 lives, cases reach 1,561, https://timesofindia.indiatimes.com/world/rest-of-world/dr-congos-ebola-outbreak-claims-506-lives-cases-reach-1561/articleshow/132219678.cms
  64. Ebola deaths in Congo top 500 as health workers threaten to strike, https://apnews.com/article/congo-ebola-health-workers-strike-deaths-ituri-1831766b125395f48ff626fbf664fb36
  65. Health workers fighting Ebola go on strike after months without pay, https://www.washingtonpost.com/world/2026/07/09/congo-health-workers-fighting-ebola-go-strike-after-months-without-pay/
  66. Ebola death toll in Congo reaches 600, as new cases suspected in previously unaffected provinces, https://apnews.com/article/congo-ebola-outbreak-deaths-957589a45723dcb092c986e1ec17da07
  67. Ebola treatment trial begins in DRC, WHO says • FRANCE 24 English - YouTube, https://www.youtube.com/watch?v=4juWS4dguOI